Mastodon Pallimed

Monday, February 16, 2009

AAHPM/HPNA Annual Assembly Preview: Thursday

(In 2007 and 2008 I posted previews for the AAHPM/HPNA Annual Assemblies. I started doing the preview because one of my favorite things about conferences is talking to other people to see what they are interested in, so feel free to comment on which sessions you are excited about. If you are giving any of these talks, I encourage you to leave some comments to get more people aware of your talk. There are some good ones!

This year the Annual Assembly is in Austin, TX from Wednesday March 25th until Saturday, March 28th.)

(Previous posts - Conference Overview, Wed Pre-Cons - AAHPM, Wed Pre-Cons - HPNA)

For the rest of the days of the conference I am not going to mention every single talk but point out what I feel are the highlights of the day, or if I just want to make a silly/witty/whatever comment on a particular title.

Opening Plenary Session: The Nature of Suffering and the Goals of Palliative Care
Eric Cassell, MD MACP, Weill Medical College of Cornell University & Betty Ferrell, PhD RN FAAN, City of Hope

This sounds like a great plenary session to open the main conference. I am very excited to hear these two talk about how people interpret suffering within themselves and see the suffering of others. I have not yet read Cassell's classic 1991 book "The Nature of Suffering and the Goals of Medicine" so if any readers would like to comment on their experience with that book please do. I am sure this talk will make me want to go out to buy it soon after the conference.

Autonomy Run Amok: Refashioning End-of-Life Decision Making
J. Andrew Billings, MD, Harvard Medical School and Massachusetts General Hospital

My peers from Kansas City have all agreed this is the talk we want to go to for the early session. Billings is a great speaker and the theme of autonomy runs through much of medical decision making in palliative care. When autonomy stomps all over other ethical principles the debris left over could be labeled moral distress

AAHPM/PDIA Community Leadership Award Presentation: Pallimed Founder and Contributors:
Drew Rosielle, MD, Medical College of Wisconsin
Christian T. Sinclair, MD, Kansas City Hospice and Palliative Care

What a fascinating pair of speakers! I already know you will be astounded by the verbal gymnastics and striking visual images compiled to entertain and inform. Seriously, we are just very humbly pleased to be formally recognized and would love to see you at the awards ceremony. Yes you have to pay $30 for lunch but we hope to see you there!

Special Interest group (SIG) Symposia:
A Fulfilling Practice in Hospice and Palliative Medicine: How Do
You Get There?
Giovanni Elia, MD, San Diego Hospice and The Institute for Palliative Medicine

One of the first sessions presented by a SIG. This is a great way for the SIG's to get involved and present topics relevant to their membership. This one is really a forum of different HPM doctors talking about all the different ways to be a hospice and palliative medicine physicians. The variety of clinical arenas and involvement would surprise most people outside our field.

Controversies in Forgoing Artificial Nutrition and Hydration in Pediatric Palliative Care
David M. Steinhorn, MD, Children’s Memorial Hospital and Northwestern University
Melody L. Hellsten, MS APRN-BC PNP, University of Texas Health Science Center–San Antonio
Joel E. Frader, MD, Children’s Memorial Hospital and Northwestern University

On one hand an acceptable medical practice for adults should apply in principle to children as well. But what are the issues and qualities of pediatric care that actually change parts of the equation? It cannot simply be surrogate decision making since the same issues apply to patients with dementia or other impaired decision making. But those of us who have worked with pediatric palliative care challenges understand this 'feels' different. I am glad this issue is being explored at this conference.

Update on Palliative Care for Patients with HIV/AIDS: Inpatient, Outpatient, and International Perspectives
Jessica Merlin, MD MBA, Hospital of the University of Pennsylvania
Peter Selwyn, MD MPH, Montefiore Medical Center, Albert Einstein College of Medicine
Rodney O. Tucker, MD, University of Alabama at Birmingham Center for Palliative Care
Liliana De Lima, MHA, International Association of Hospice and Palliative Care
Mimi Rivard, MSN APN, St. Vincent’s Medical Center

I don't have much to say about the talk itself besides noting the diminishing HIV patient population in palliative care arenas with the advent of HAART has made the current crop of palliative care trainees less aware of HIV Palliative Care treatment options. I did want to point out the name Jessica Merlin a ID fellow with a strong interest in Palliative Care who is also the Vice Chair of the Professionals in Training SIG. The fact that she got this talk submitted and accepted with such a strong slate of speakers is impressive for not even really being in our field yet and still an ID fellow. She impressed a lot of people with her energy at last year's meeting.

Working in the World of Chronic Kidney Disease: Where, Oh Where, Is Palliative Care?
Charles V. Wellman, MD FAAHPM
Janice Scheufler, RPh PharmD FASCP
Hospice of the Western Reserve

Any bets on if they will sing in this session? A nominee for best title this year. And a good topic given the seeming conflict between the Medicare Hospice Benefit and the Medicare Dialysis Benefit.

Case Conference I

While a non-descript name, this session and the other three have been a product of the PIT-SIG to highlight rising learners in palliative care from multiple disciplines. I will have an upcoming post featuring the various topics and speakers. Try to get to at least one.

Reblog this post [with Zemanta]

Monday, February 16, 2009 by Christian Sinclair ·

Email and RSS Readers: Migration Happening Soon

A quick heads up for email and RSS subscribers: Google is transferring our feed to their own servers from Feedburner in the next few weeks (deadline Feb 28, 2009). The process is supposed to be smooth, but one medical blogger has already lost some email subscribers. You should not notice a thing, but if you notice no posts or emails from Pallimed for more than two weeks, you may want to try resubscribing.

Hopefully, this should all go well. Let us know if you have any problems.

by Christian Sinclair ·

Friday, February 13, 2009

Cancer pain intensity and analgesic complexity

ResearchBlogging.orgJournal of Clinical Oncology has an intriguing paper on cancer pain intensity and 'complexity' of cancer pain management. The data come from a prospective, Canadian study of ~600 'advanced' cancer patients referred for palliative care consultation (including inpatient and hospice-based settings). 21% reported severe, at least 7/10 pain, at initial assessment. They defined pain control as pain 3/10 or less and 3 or fewer breakthrough doses for at least 3 consecutive days.

The findings are interesting on a couple levels. First is the natural history data. Median time to pain control was 4 days for patients reporting mild pain at baseline, compared to 22 days with those reporting severe pain. In fact it looks like (I say 'looks like' because this is me eye-balling a Kaplan-Meier curve) there is a group (~15% of patients with baseline moderate or severe pain) who don't achieve stable pain control (as defined above) even after 90 days. In multivariate analysis having baseline moderate to severe pain, suspected neuropathic pain, and age less than 60 years were independently associated with longer time to pain control. Psychological factors, at least how they measured them, did not predict length of time to pain control in the multivariate analysis. Increased baseline pain also predicted increased use of adjuvant analgesics and higher final opioid dose (a median of 72 vs 12 mg of oral morphine equivalents, compared with baseline mild pain patients).

Well, so what? Patients who hurt more need more meds and it takes longer to achieve decent analgesia. On its face that isn't surprising, and could seem to be quite a dull finding. It isn't necessarily however. First off this is supporting data that numeric rating scale reports do tell us something about a group of patients (ie - allow comparisons between groups of patients as opposed to only the strict interpretation of NRS data that they are meaningful only on an individual basis to compare, say, treatment response after initiating a new analgesic in an individual patient). (Yes, this has been a point of some controversy, and the paper's discussion section addresses it further if you're interesting). Second, it's supporting data that for patients who present with severe pain we should not necessarily be 'starting low and going slow' and should in fact be more aggressive. I suspect however that most of us do this anyway because it's, well, the obvious thing to do (much of the time).

Finally, however, I am left wondering about this last 15%: the ones that never achieve good control (at least as defined by the criteria above which has the major limitation of not being based in how patients themselves rate their satisfaction with their analgesia: are they happy with their pain relief? Can they do the things they want to do despite having, say, 5/10 pain, etc.?) Most of us who practice in referral cancer pain settings (that is, for example, an oncologist has to refer a patient to me for pain in order for me to see that patient) tend to get referred the patients with the toughest to control pain syndromes (intolerable side effects, lack of efficacy of multiple agents, etc.). This, then, is a patient population near and dear to my heart, and one that hasn't been studied very closely, but is actually quite central to many of us with referral-type palliative practices. Talking with others about this, it there seems to be a bi-modal distribution of patients with cancer pain: the (thankfully vast) majority who do just fine with all our 'usual moves' vs. the (thankfully) few who don't seem to gain particular benefit (whether it's in pain rating, function/mobility, mood/ability to enjoy life) from most things we do, and often with a tremendous amount of suffering tacked on (not least of which are the side effects from the treatments we prescribe). It's these few I'm particularly interested in - who they are, how we can recognize them early, why they respond differently to our 'usual moves' (yes I'm sure it's a combination of genetic, psychiatric, and otherwise neurobiologic reasons but what exactly does that mean anyway), and what we can do about it (because I wonder if they need a distinctly different approach than running them through the toolkit which happens to work for most other patients)....

So, sure, that was a rambling presentation of some thoughts that have been meandering through my mind lately, but I am hopeful that as our research base matures these questions will begin to get answered.

R. L. Fainsinger, A. Fairchild, C. Nekolaichuk, P. Lawlor, S. Lowe, J. Hanson (2008). Is Pain Intensity a Predictor of the Complexity of Cancer Pain Management? Journal of Clinical Oncology, 27 (4), 585-590 DOI: 10.1200/JCO.2008.17.1660

Friday, February 13, 2009 by Drew Rosielle MD ·

Shall we panic?

Apparently the FDA is planning on undertaking a wide-reaching risk mitigation program for prescription opioids. The press-release implies it's focused on 'working with industry' to ensure their safe and appropriate use. No particular mention is given to working with clinicians and patients, or where their voice will be in all this (although that has been mentioned in other blog posts on the topic).

At this point we know very little about this, or what it will look like, but I am confident anything which smells of further scrutiny will increase the already existent barriers to chronic opioid therapy. I am still waiting for any sort of evidence that inappropriate clinician prescribing (e.g. either reckless or not done with analgesic/therapeutic intent) is a major/systematic contributor to the rise of prescription drug abuse, although if you read the literature many people seem to believe this even without supporting data. I don't want to suggest risk abatement etc. are bad things, of course they aren't, but if not done well/sanely it will be our patients who suffer the consequences.

I am not a policy maven, but know that some pain policy types read this blog and would appreciate any comments, links, or organizing information about this.

If you're interested in some thoughtful common sense about opioids for chronic pain the current issue of Journal of Pain has 3 American Pain Society guidelines about the topic (issue table of contents here, guidelines are towards the top). The one I'd highlight in particular, persuant to the above topic, is the one on research gaps which thoroughly describes just what we don't know.

by Drew Rosielle MD ·

Methadone and the QTc

Annals of Internal Medicine has published consensus guidelines for QT interval monitoring for patients on methadone.

First-off I'd like to commend this paper for containing the following sentence which nearly made me spit my coffee out for its combination of human-non-readable electrophysiology babble with the big reveal that some electrophysiologist somewhere named a a gene 'human cardiac ether a go-go.'

'The most common mechanism of drug-induced QT prolongation and torsade de pointes is blockade of the human cardiac ether à go-go–related gene (hERG), which encodes Ikr, the delayed-rectifier potassium ion current.'
That aside, the guidelines review the history of methadone and QT prolongation/torsades, review the evidence (much of it highly inferential - especially the autopsy series - although some based in prospective studies) suggesting that methadone is associated with QT prolongation (to me this evidence is quite solid) and cardiac arrhythmias and sudden cardiac death (the actual rates of this/clinical relevance of this seems to be completely undefined as of yet).

They go onto make reasonable recommendations, more or less based on expert opinion by their consensus panel. The 100mg/day figure is based, again, on some difficult-to-interpret reports suggesting the risk of arrhythmia is dose-related and most often occurs in patients on over 100 mg daily.

Recommendation 1 (Disclosure): Clinicians should inform patients of arrhythmia risk when they prescribe methadone.

Recommendation 2 (Clinical History): Clinicians should ask patients about any history of structural heart disease, arrhythmia, and syncope.

Recommendation 3 (Screening): Obtain a pretreatment electrocardiogram for all patients to measure the QTc interval and a follow-up electrocardiogram within 30 days and annually. Additional electrocardiography is recommended if the methadone dosage exceeds 100 mg/d or if patients have unexplained syncope or seizures.

Recommendation 4 (Risk Stratification): If the QTc interval is greater than 450 ms but less than 500 ms, discuss the potential risks and benefits with patients and monitor them more frequently. If the QTc interval exceeds 500 ms, consider discontinuing or reducing the methadone dose; eliminating contributing factors, such as drugs that promote hypokalemia; or using an alternative therapy.

Recommendation 5 (Drug Interactions): Clinicians should be aware of interactions between methadone and other drugs that possess QT interval–prolonging properties or slow the elimination of methadone.
They also note that: Panel recommendations are not intended to supplant clinical judgment or patient preferences and may not apply to patients with terminal, intractable cancer pain. I myself tend to get baseline EKGs on patients who I expect have prolonged prognoses (many months at least) but not usually for those closer to death. What data (all observational) we have on methadone in advanced cancer patients has supported its safety.

by Drew Rosielle MD ·

Monday, February 9, 2009

AAHPM/HPNA Annual Assembly Preview: Wed Pre-Conf HPNA


(In 2007 and 2008 I posted previews for the AAHPM/HPNA Annual Assemblies. I started doing the preview because one of my favorite things about conferences is talking to other people to see what they are interested in, so feel free to comment on which sessions you are excited about. If you are giving any of these talks, I encourage you to leave some comments to get more people aware of your talk. There are some good ones!

This year the Annual Assembly is in Austin, TX from Wednesday March 25th until Saturday, March 28th.)

(Previous posts - Conference Overview, Wed Pre-Cons - AAHPM)

Wednesday March 25th Pre-Conference Workshops - HPNA

All Day Sessions (8a-5p)

Generalist Clinical Review Train the Trainer
HPNA certifies educators to help maintain quality education around the country and this is the main avenue for educating the local leaders of palliative care nursing to help build a palliative nursing workforce that will be in more and more demand. The pick for anyone wishing to educate other nursing professionals.

Withholding/Withdrawing Life Sustaining Treatments
This is a perfect topic for an all-day session, but I bet it will be an exhausting one given the subject matter and the medical, legal, ethical and cultural areas to be covered. It is a great addition to have Christy Torkildson to give cases from a pediatric perspective. They even used the new hot phrase in medicine 'moral distress' in the description blurb.

Half-Day Sessions


Through the Looking Glass: Making Sense of APN Billing
Two points for a very interesting title. Negative points will be awarded if Connie Dahlin only uses a couple of cute Alice in Wonderland clip art to decorate her slides. Exponential positive points will be awarded if she ties in the categorization of the Lewis Carrol book as literary nonsense to APN billing or the confusing themes of altered time and space to APN billing. Billing for APN's is an area that desperately needs someone to work towards consistent models across different states. Hello...President Obama and health care reform?

Precise Pharmacopalliation of Advanced Noncancer Illness
Fancying myself a bit of a hobbyist wordsmith, I was enamored by my new favorite medical term, 'pharmacopalliation.' It takes a while to say, type and write, but I am planning on incorporating it wherever I can. Thank goodness this session is not only focusing on which medicines to start but actually discussing when and how to stop medications. Another area the FDA, NIH and others could put a little time and attention to. Hello...President Obama and health care reform? (Can you figure out what the #1 issue is for HPM in 2009 yet?)

Don't Panic! The CoPs are Here! How to Be Sure You Are Ready!
See what I said about the CoPs and conferences? I bet this is a very crowded seminar. And they promise to have a robust question and answer session! They should get a gold star for the title as well. So many different ways to read into it...the whole CoPs and police theme.

Initiating and Maintaining a Palliative Care Service for APN's
I presume this session is talking about palliative care services without doctors, but there may be some great tips for Palliative Care Services even with doctors and APN's. The blurb does not specify which model it is most clearly articulating. The APN's I have worked with over the years have been some of the best clinicians I have ever worked with. I find their role invaluable.


Evening Session


CPC Nurse Workshop - Cultivating Palliative Advanced Practice Nursing Through Mentoring
This was listed under the AAHPM section but I thought I would include it hear for continuity with the other nursing themes. Bold choice of a 6-10pm time, but it is also free and the faculty looks diverse and outstanding so I expect this to be a well attended session.

Monday, February 9, 2009 by Christian Sinclair ·

HPM Issues 2009:
#2 Making Sense of the new Medicare Hospice Conditions of Participation

(This is the fourth in a series of 5 posts (#5, #4, #3) about issues in hospice & palliative medicine I think will be important in the next year. Feel free to disagree!)*

#2 Making Sense of the new Medicare Hospice Conditions of Participation
We have not covered a ton of the bureaucratic and administrative sides of hospice or palliative medicine here at Pallimed. I would recommend the Hospice Blog by Hospice Guy for a sharper focus on such topics (all Hospice Blog COP related posts here). The Conditions of Participation (COP) for the Medicare Hospice Benefit is basically a rule book for how hospices must operate since all hospice derive a majority of their revenue from Medicare. The new COPs went into effect on December 2nd and hospices are trying to best interpret all of the subtle and drastic rule changes that were made.

Thankfully, Medicare did have a period for input from hospice agencies and other advocate groups before publishing the final COPs. It is interesting how many conferences, software programs, and seminars have cropped up to help indicate what kind of demand there is to KNOW that your agency is compliant with the regulations.

Some key quotes from Hospice Guy:

There are regulations in the new COPs that are hard to accomplish (especially for small hospices). There are also some that nobody seems to fully understand. I don't think Medicare even understands what they want us to do for some of them. I have spent the last six months putting things in place, but have been dragging my feet on a couple of issues hoping that Medicare would clarify what, exactly, they want us to do. Those clarifications have not come. Clearly, we can't wait forever.

----

I do think some of the changes are going to be very hard on small hospices and somewhere near impossible for small rural hospices that cover hundreds of miles of territory. I'm not sure that the provision that each patient must be seen by a nurse, social worker, and chaplain within four calendar days of admission is possible or practical for some of those small rural hospices.
Make sure to read his COP related posts comments from other hospice administrators if this is a topic you are interested in. And contribute if you have a particular view or insight on the COP's

As the new COPs are implemented it will be interesting to see what unintended consequences shake out of the process. Will referring doctors be frustrated by a possible increase amount of paperwork or contact in an effort to better document collaboration with a primary doctor? Will new processes put in place to meet compliance standards result in less time, money and effort directed towards patient care for 'non-essential' (or essential) programs? What will be interpreted as a hard and fast law instead of a guideline as the original authors may have intended?

Time will tell. (Sorry about the cliche. It's getting late!)

by Christian Sinclair ·

Friday, February 6, 2009

Lidocaine patch for cancer surgery pain


Supportive Care in Cancer has published a randomized, double-blind, placebo-patch controlled trial of the 5% lidocaine patch for postsurgical incisional pain in cancer patients. It involved an unfortunately small number of patients (28 randomized, 18 completed the trial) who had greater than one month of pain in/near their surgical site (most had breast or lung surgeries), at least 4/10, and with some 'neuropathic features' (had to have burning, paresthesias, or allodynia). They received active (up to 3 at a time, worn 18 hours a day) or placebo patch each for a month, then switched. The study was powered for 50 patients per arm.

There were no statistically significant differences in pain between groups at any times (reported worst, least, average, current pain intensity) - and even eye-balling the graphs it's tough to say there were consistent trends. Pain interference was modestly (and statistically significantly) improved with the active patch (e.g. interference with work), but that was it. Unfortunately I don't think we can conclude anything from these data. This seemed to be a well-thought out, well-designed study, with reasonable outcomes, but there just weren't sufficient number of subjects to tell a difference. Even in the best studies on the patch (all involving post-herpetic neuralgia) which showed significant improvement in the active patch subjects - the average improvement was modest (in the ballpark of 1.5 points on a 0-10 pain scale) - and one is never going to show a significant difference with these small numbers.

This raises the question - why even pay attention to a symptomatic therapy whose effects are so modest you need 100+ patients to even demonstrate a little improvement? Especially one as costly as the lidocaine patch? Cost concerns aside, I continue to use the patch because 1) it's incredibly safe and well tolerated (no drug interactions or really no demonstrable side effects other than skin stuff), and 2) a small minority of my patients who use it report tremendous benefit - solid pain relief, opioid sparing, etc. etc. (a substantial minority in addition report modest improvements with it). It's possible that the #2 phenomenon is largely placebo (especially since there's yet to be any controlled data clearly demonstrating the patch is beneficial outside of postherpetic neuralgia), and in some ways the lidocaine patch seems to be a perfect storm of a placebo: a prescription-only treatment containing a 'numbing medicine' with fancy packaging that you apply right where it hurts. Sounds good to me. #2 is why I keep using it, but I remain agnostic about what I'm actually prescribing, and I'm curious as to what others think of the patch. From a health-systems standpoint I understand why many insurers and hospices won't use it.

ResearchBlogging.orgAndrea L. Cheville, Jeff A. Sloan, Donald W. Northfelt, Anand P. Jillella, Gilbert Y. Wong, James D. Bearden III, Heshan Liu, Paul L. Schaefer, Benjamin T. Marchello, Bradley J. Christensen, Charles L. Loprinzi (2009). Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB) Supportive Care in Cancer DOI: 10.1007/s00520-008-0542-x

Friday, February 6, 2009 by Drew Rosielle MD ·

Conflicts over life-prolonging care in NEJM

Last week's NEJM has an all-too familiar case discussion about a protracted conflict regarding life-prolonging treatment in a vulnerable, brain-injured man with a dismal prognosis. A case is presented, followed by 3 different discussants all proposing different 'next steps' (essentially more talk, continue life-prolonging care, or discontinue life-prolonging care). Readers can then vote as to which next step they most support, and add comments. Hundreds have done so, with a lot of interesting, and very wise (mostly) comments.

My own comment (which is now deeply buried) discusses the fact that this occured in a state in which the legal next of kin defaults as the legal decision maker and much of the conflict revolves around this NOK who was legally empowered to be a decision maker for a patient without any evidence that he 1) wanted to be; 2) the patient wanted him to be; or 3) that he was even willing to abide by the most basic of supposedly-valid proxy decision-making principles such as substituted judgment or 'best-interest.' While not having a law or court ruling which delinates who is a decision-maker creates its own set of problems, it seems particularly crazy to me to have laws/court rulings which mandate someone as a decision-maker based on some version of closeness-of-relation, especially given that a substantial minority of patients when they actually designate a health care power of attorney don't even name their spouse! Most do, of course, but some, presumably for very good reasons, would rather have their sister or daughter make those decisions for instance....

Anyway - it's great to see such a case given such prominence in the NEJM - and you can still 'vote' until February 11.

by Drew Rosielle MD ·

Pall-Pourri

1)
Journal of Clinical Oncology
has a 'phase II' study of an outpatient palliative care clinic in a Canadian cancer center. It is a prospective observational study of ~150 adult cancer outpatients who were referred to a palliative care clinic and received a comprehensive consultation (90 to 120 minutes; seen by both a nurse case manager and physician as well as at times a social worker and psychiatrist). Baseline, 1 week, and 1 month symptoms and patient satisfaction were measured. This is an uncontrolled observational study of course, and it's impossible to ascribe any changes due to the interactions with the palliative care team, but it provides some interesting natural history data which could provide baseline for further studies. Grossly speaking, most symptoms improved ~10% (across the cohort, there was an average improvement of ~1 point on a 0-10 point symptom scale for most symptoms) at 1 week and month. An accompanying editorial contextualizes the research better than I could.

2)
In a similar vein, Cancer has a descriptive series characterizing ICU patients (at a US cancer center) who receive palliative care consultation. It's an interesting read to see what another team does, at another institution, and to just get a sense of who these patients are - they are quite sick, with a high mortality over 50% in-ICU death rate, and seen by palliative care late (average of 10th day of ICU stay, with mean overall ICU length of stay of 16 days). 'Late' here is meant descriptively, not necessarily as a judgment.

3)
The NEJM continues the discussion about the risk of sudden death with typical and atypical antipsychotics with a retrospective case-control analysis again demonstrating an increased risk of death for patients receiving those agents. An accompanying editorial floats the idea of not only maybe people should be using these less but that there should be outright restrictions on their use (comparing this to the monitoring that happens with clozapine for agranulocytosis, particularly given that the risk of sudden cardiac death seems to be a lot higher than the hematologic risks associated with clozapine) for off-label and 'non-evidence based' uses. I don't know if this is a good idea or not; however it would seem to make the impetus for expanding the evidence-base for antipsychotics for the acute/short-term management of delirium more acute.

4)
Annals of Internal Medicine has a sobering analysis of allocating 'life support' resources (ventilators) during a public health emergency. While wonkish, it's very readable, and given the stakes if something like this ever happened I read it with fascination. Their overall argument that neither age, nor comorbidity, nor likelihood of short-term survival alone should decide how the resources are used (all of which have been proposed at times) - they should all be incorporated. Who actually makes those decisions during a crisis, of course, is another story. If this happens, palliative care professionals will be finding ourselves caring for patients excluded from life-prolonging treatments, and are widely mentioned in planning documents (see this from the feds).

by Drew Rosielle MD ·

Pallimed | Blogger Template adapted from Mash2 by Bloggermint